Immediate Impact

1 from Science/Nature 50 standout
Sub-graph 1 of 25

Citing Papers

A dual diffusion model enables 3D molecule generation and lead optimization based on target pockets
2024 Standout
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
2023 Standout
1 intermediate paper

Works of Olaf Prien being referenced

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
2019
From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors
2005

Author Peers

Author Last Decade Papers Cites
Olaf Prien 136 124 68 96 16 343
Weifang Shan 95 151 23 101 13 332
Shevan Silva 154 69 24 144 17 350
Donna Wei 49 146 63 140 14 374
Andrew K. Kwegyir‐Afful 182 36 20 241 12 381
Martina Fitzek 25 91 26 212 21 365
Takashi Shirakawa 34 42 64 150 22 386
Bertrand Heckmann 57 86 16 229 16 392
Olli Törmäkangas 245 53 71 103 8 342
L. R. HUGHES 81 79 10 198 14 394
Jingle Xi 31 78 18 144 10 327

All Works

Loading papers...

Rankless by CCL
2026